Posters

Refractive and visual stability in patients implanted with clear non-refractive corneal inlay: single center clinical results

Poster Details

First Author: G. Parkhurst UNITED STATES

Co Author(s):                        

Abstract Details

Purpose:

To evaluate my cohort of subjects implanted with a Raindrop® Near Vision Inlay (ReVision Optics, Inc., Lake Forest, CA, USA) as part of a multicenter prospective FDA IDE study.

Setting:

Parkhurst NuVision, San Antonio, TX, USA

Methods:

Thirty-nine (39) emmetropic presbyopes (MRSE: -0.50 D to +1.00 D) were implanted with the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond flap, centered over the light-constricted pupil. The implant is designed to change the curvature of the overlying cornea creating a gradient of power that improves near and intermediate vision. ETDRS visual acuities (near/intermediate/distance), manifest refraction, and Add powers were collected at preop, 1M, 3M, 6M, 9M, 12M, and 18M.

Results:

At 18M (n=38), average monocular near and intermediate visual acuities (logMAR) improved from preop (UNVA: 0.63 to 0.06, UIVA: 0.45 to 0.15). More than 84% of subjects were 20/25 or better (binocular UCVAs) at near, intermediate, and distance. MRSE remained stable with more than 95% of subjects with less than 0.50 D change 3M to 18M. Average Add power decreased from preop (+1.66 D) to 1M (+0.13 D) and remained stable out to 18M (+0.11 D).

Conclusions:

Raindrop Inlay improves near and intermediate vision and provides full range of functional binocular vision. Refraction and Add power stabilizes shortly after implantation and remains consistent out to 18 months.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One or more of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented